Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
Returns on capital
Sangamo Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
861.6%
avg -14.5%
ROIC
-566.4%
avg -107.1%
ROA
-205.8%
avg -58.1%
Analysis
ROE is currently the strongest return metric at 861.6% versus its period average of -14.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alexander D. Macrae Ch.B MRCP | Chief Executive Officer, President & Director | USD 930.26K | 63 | — | — |
Nathalie Dubois-Stringfellow | Senior Vice President & Chief Development Officer | USD 585.22K | 64 | 328.73K | 0.08% |
Scott Willoughby | Senior Vice President, Chief Legal Officer & Corporate Secretary | USD 569.65K | 51 | — | — |
Gregory Davis | Head of Research & Technology | — | 56 | — | — |
Louise Wilkie | Head of Global Corporate Communications & Investor Relations | — | — | — | — |
David Ojala | Scientist II - Discovery & Translational Research | — | — | — | — |
Nikunj Jain | Interim CFO and Principal Financial & Accounting Officer | — | 46 | 235.29K | 0.06% |
Phillip Ramsey | Chief Technical Officer | — | — | — | — |
Stephanie J. Seiler | Vice President and Head of Business Development & Alliance Management | — | — | — | — |
Compensation is shown in the reported currency; data updated Jun 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 25, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$106,878.01
Net Transaction Value
−$106,878.01
Net selling
Most Active
Davis Gregory D
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 22, 26Apr 22, 2026 | Davis Gregory D Direct | Sell | $17.7K$17,694.16 |
| Apr 21, 26Apr 21, 2026 | Dubois-Stringfellow Nathalie Direct | Sell | $89.2K$89,183.85 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $106,878.01 over the last 12 months. That adds up to net selling of $106,878.01. Davis Gregory D was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -29.2% | +68.7% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -29.2% over three years. Forward estimates point to Revenue at +68.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Sangamo Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SGMO's management, answered from reported figures.
Who manages SGMO?
Sangamo Therapeutics, Inc. (SGMO) lists 9 active executives. The top listed executive is Gregory Davis, Head of Research & Technology.
Are SGMO insiders buying or selling?
Recent insider activity shows net selling of $815,851.32.
Continue the stock analysis
Jump to another research area for this company.